{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:59:36Z","timestamp":1772557176775,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13048-018-0391-2","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T11:53:55Z","timestamp":1519991635000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Comparison of benign peritoneal fluid- and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3525-138X","authenticated-orcid":false,"given":"Cindy M.","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie L.","family":"Oakes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Muto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross S.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Wing","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,2]]},"reference":[{"key":"391_CR1","unstructured":"U.S. Cancer Statistics Working Group. United States cancer statistics: 1999\u20132013 incidence and mortality web-based report. https:\/\/www.cdc.gov\/cancer\/ovarian\/statistics\/index.htm (accessed 17 Aug 2017)."},{"key":"391_CR2","unstructured":"National Cancer Institute: Surveillance, Epidemiology, and End Results Program. https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html (accessed 17 Aug 2017)."},{"issue":"Suppl 10","key":"391_CR3","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/1097-0142(19951115)76:10+<2004::AID-CNCR2820761317>3.0.CO;2-G","volume":"76","author":"SJ Skates","year":"1995","unstructured":"Skates SJ, Xu FJ, Yu YH, Sjovall K, Einhorn N, Chang Y, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76(Suppl 10):2004\u201310.","journal-title":"Cancer"},{"key":"391_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.humpath.2012.01.005","volume":"43","author":"MM Streppel","year":"2012","unstructured":"Streppel MM, Vincent A, Mukherjee R, Campbell NR, Chen SH, Konstantopoulos K, et al. Mucin 16 (cancer antigen 125 ) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol. 2012;43:10.","journal-title":"Hum Pathol"},{"key":"391_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3322\/caac.20113","volume":"61","author":"D Jelovac","year":"2011","unstructured":"Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61:3.","journal-title":"CA Cancer J Clin"},{"key":"391_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1001\/jama.2011.766","volume":"305","author":"SS Buys","year":"2011","unstructured":"Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305:22.","journal-title":"JAMA"},{"key":"391_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygyno.2016.03.036","volume":"142","author":"KDP Dorayappan","year":"2016","unstructured":"Dorayappan KDP, Wallbillich JJ, Cohn DE, Selvendiran K. The biological significance and clinical applications of exosomes in ovarian cancer. Gynecol Oncol. 2016;142:1.","journal-title":"Gynecol Oncol"},{"key":"391_CR8","doi-asserted-by":"publisher","unstructured":"Crow J, Atay S, Banskota S, Artale B, Schmitt S, Godwin AK. Exosomes as mediators of platinum resistance in ovarian cancer, Oncotarget. 201; doi: https:\/\/doi.org\/10.18632\/oncotarget.14440 .","DOI":"10.18632\/oncotarget.14440"},{"key":"391_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1541-7786.MCR-16-0191","volume":"15","author":"K Nakamura","year":"2017","unstructured":"Nakamura K, Sawada K, Kinose Y, Yoshimura A, Toda A, Nakatsuka E, et al. Exosomes promote ovarian cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells. Mol Cancer Res. 2017;15:1.","journal-title":"Mol Cancer Res"},{"key":"391_CR10","first-page":"6","volume":"33","author":"J Zhou","year":"2015","unstructured":"Zhou J, Gong G, Tan H, Dai F, Zhu X, Chen Y, et al. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. Onc Rep. 2015;33:6.","journal-title":"Onc Rep"},{"key":"391_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nbt.2886","volume":"32","author":"H Im","year":"2014","unstructured":"Im H, Shao H, Park YI, Peterson VM, Castro CM, Weissleder R, et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat Biotechnol. 2014;32:5.","journal-title":"Nat Biotechnol"},{"key":"391_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1073\/pnas.1017300108","volume":"108","author":"AM Karst","year":"2011","unstructured":"Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. PNAS. 2011;108:18.","journal-title":"PNAS"},{"key":"391_CR13","first-page":"10","volume":"7","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Kwok JS-L, Choi P-W, Liu M, Yang J, Singh M, et al. Pinin interacts with C-terminal binding proteins for RNA alternative splicing and epithelial cell identity of human ovarian cancer cells. Oncotarget. 2016;7:10.","journal-title":"Oncotarget"},{"key":"391_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13046-016-0307-1","volume":"35","author":"J Yan","year":"2016","unstructured":"Yan J, Jiang J-Y, Meng X-N, Xiu Y-L, Zong Z-H. MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression. J Exp Clin Ca Res. 2016;35:31.","journal-title":"J Exp Clin Ca Res"},{"key":"391_CR15","first-page":"7","volume":"1","author":"J Li","year":"2016","unstructured":"Li J, Hu K, Gong G, Zhu D, Wang Y, Liu H, et al. Upregulation of miR-205 transcriptionally suppresses SMAD4 and PTEN and contributes to human ovarian cancer progression. Sci Reports. 2016;1:7.","journal-title":"Sci Reports"},{"key":"391_CR16","first-page":"13","volume":"7","author":"X Meng","year":"2016","unstructured":"Meng X, Muller V, Milde-Langosch K, Trillsch F, Pantel K, Schwrzenbach H. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 2016;7:13.","journal-title":"Oncotarget"},{"key":"391_CR17","first-page":"7","volume":"29","author":"CLA Yeung","year":"2016","unstructured":"Yeung CLA, Co N-N, Tsuruga T, Yeung T-L, Kwan S-Y, Leung CS, et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016;29:7.","journal-title":"Nat Commun"},{"key":"391_CR18","first-page":"7","volume":"7","author":"RL Wu","year":"2105","unstructured":"Wu RL, Ali S, Bandyopadhyay S, Alosh B, Hayek K, Daaboul MHD, et al. Comparative analysis of differentially expressed miRNAs and their downstream mRNAs in ovarian cancer and its associated endometriosis. J cancer Sci Ther. 2105;7:7.","journal-title":"J cancer Sci Ther"},{"key":"391_CR19","first-page":"4","volume":"13","author":"E Kipps","year":"2103","unstructured":"Kipps E, DSP T, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Ca. 2103;13:4.","journal-title":"Nat Rev Ca"},{"key":"391_CR20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1177\/1933719117699545","volume":"24","author":"T Roskams","year":"2017","unstructured":"O DF, Roskams T, Van den Eynde K, Vanhie A, Peterse DP, et al. The presence of endometrial cells in peritoneal fluid of women with and without endometriosis. Reprod Sci. 2017;24:2.","journal-title":"Reprod Sci"},{"key":"391_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ccr.2013.10.013","volume":"24","author":"R Perets","year":"2013","unstructured":"Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell. 2013;24:6.","journal-title":"Cancer Cell"},{"key":"391_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1349-7006.2000.tb00967.x","volume":"91","author":"Y Yoshikawa","year":"2000","unstructured":"Yoshikawa Y, Mukai H, Hino F, Asada K, Kato I. Isolation of two novel genes, down-regulated in gastric cancer. Jpn J Cancer Res. 2000;91:5.","journal-title":"Jpn J Cancer Res"},{"key":"391_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nm.2492","volume":"17","author":"KM Nieman","year":"2011","unstructured":"Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17:11.","journal-title":"Nat Med"},{"key":"391_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1538-7445.AM2013-16","volume":"73","author":"TL Yeung","year":"2013","unstructured":"Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, et al. TGF-b modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Ca Research. 2013;73:16.","journal-title":"Ca Research"},{"key":"391_CR25","doi-asserted-by":"publisher","unstructured":"Kongkham PN, Northcott PA, Ra YS, Nakahara Y, Mainprize TG, Croul SE, et al. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. Cancer Res. 2008; https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2169 .","DOI":"10.1158\/0008-5472.CAN-08-2169"},{"key":"391_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0167-4781(97)00141-3","volume":"1395","author":"F Muller-Pillasch","year":"1998","unstructured":"Muller-Pillasch F, Wallrapp C, Bartels K, Varga G, Friess H, Buchler M, et al. Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer. Biochim Biophys Acta. 1998;1395:1.","journal-title":"Biochim Biophys Acta"},{"key":"391_CR27","first-page":"6","volume":"77","author":"Y Pan","year":"2011","unstructured":"Pan Y, Jiao J, Zhou C, Cheng Q, Hu Y, Chen H. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. Pathobiology. 2011;77:6.","journal-title":"Pathobiology"},{"key":"391_CR28","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1097\/IGC.0000000000001105","volume":"9","author":"N Kenda Suster","year":"2017","unstructured":"Kenda Suster N, Frkovic Grazio S, Virant-Klun I, Verdenik I, Smrkolj S. Cancer stem cell-related marker NANOG expression in ovarian serous tumors: a clinicopathological study of 159 cases. Int J Gynecol Cancer. 2017;9:2006.","journal-title":"Int J Gynecol Cancer"},{"key":"391_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1757-2215-5-44","volume":"5","author":"MS Zaman","year":"2012","unstructured":"Zaman MS, Maher DM, Khan S, Jaggi M, Chauhan SC. Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Research. 2012;5:44.","journal-title":"J Ovarian Research"},{"key":"391_CR30","doi-asserted-by":"publisher","unstructured":"Li J, Hu K, Gong G, Zhu D, Wang Y, Liu H, et al. Upregulation of miR-205 transcriptionally suppresses SMAD4 and PTEN and contributes to human ovarian cancer progression. Sci Rep. 2017; https:\/\/doi.org\/10.1038\/srep41330 .","DOI":"10.1038\/srep41330"},{"key":"391_CR31","doi-asserted-by":"publisher","unstructured":"Shapira I, Oswald M, Lovecchio J, Khalili H, Menzin A, Whyte J, et al. Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer. 2014; https:\/\/doi.org\/10.1038\/bjc.2013.795 .","DOI":"10.1038\/bjc.2013.795"},{"key":"391_CR32","doi-asserted-by":"publisher","unstructured":"Yu PN, Yan MD, Lai HC, Huang RL, Chou YC, Lin WC, et al. Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int J Cancer. 2014; https:\/\/doi.org\/10.1002\/ijc.28399 .","DOI":"10.1002\/ijc.28399"},{"key":"391_CR33","doi-asserted-by":"publisher","unstructured":"Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, et al. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One. 2012; https:\/\/doi.org\/10.1371\/journal.pone.0034546 .","DOI":"10.1371\/journal.pone.0034546"},{"key":"391_CR34","doi-asserted-by":"publisher","unstructured":"Ye Z, Zhao L, Li J, Chen W, Li X. MiR-30d blocked transforming growth factor \u03b21-induced epithelial-mesenchymal transition by targeting snail in ovarian cancer cells. Int J Gyn Ca. 2015; https:\/\/doi.org\/10.1097\/IGC.0000000000000546 .","DOI":"10.1097\/IGC.0000000000000546"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-018-0391-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T04:16:25Z","timestamp":1660536985000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-018-0391-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,2]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["391"],"URL":"https:\/\/doi.org\/10.1186\/s13048-018-0391-2","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,2]]},"assertion":[{"value":"2 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human samples were collected at Brigham and Women\u2019s hospital under informed consent and Internal Review Board approval.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CMY, MO, and TM are employees of Hitachi Chemical Co. America, Ltd. R&D Center and the two authors, CMY and SWN have submitted a provisional patent (Appl. No. 62\/507,091) entitled, \u201cMethods for detecting ovarian cancer using extracellular vesicles for molecular analysis\u201d.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"20"}}